Australia Cracks Down on Compounded Weight Loss Drugs Amid Safety Concerns and Shortages
Table of Contents
A growing crisis surrounding off-label prescriptions and compounded versions of popular diabetes drugs like Ozempic and Mounjaro has prompted the Australian government to tighten regulations, aiming to protect public health and address widespread shortages. Initially developed to manage type 2 diabetes, these semaglutide medications have gained notoriety for their significant weight loss effects, fueling a surge in demand that has strained the system and created opportunities for potentially dangerous loopholes.
The Rise of Off-Label Use and Compounding
Approximately 66% of Australian adults are classified as overweight or obese, a figure that rises to 74% among First Nations adults and 38% among First Nations children, according to the Australian Institute of Health and Welfare. This prevalence has created a substantial market for weight loss solutions, driving demand for semaglutide drugs far beyond their intended use. While prescribing medications “off-label” – for a purpose other than what’s officially approved – is not illegal, it presents ethical and regulatory challenges, particularly when supply struggles to meet demand.
The Therapeutic Goods Administration (TGA), responsible for approving medicines in Australia, acknowledges the practice of off-label prescribing, stating it’s “a regular occurrence” often used for rare conditions or underrepresented patient groups. However, the TGA lacks the authority to prevent doctors from exercising their clinical judgment. This regulatory gap allowed a market for compounded medications to flourish – drugs mixed by pharmacists, often as replicas of the branded versions.
Safety Concerns and Regulatory Response
The proliferation of compounded medications raised serious concerns about safety and efficacy. These products bypassed the rigorous testing and quality control standards applied to TGA-approved drugs. “Compounded medicines are not required to be entered on the Australian Register of Therapeutic Goods,” explained Michael Cossetto, a partner at Bartier Perry, “so long as they are compounded by a pharmacist for a particular person.”
The situation escalated to the point where over 20,000 Australians were reportedly injecting these compounded weight loss products, leading to a rise in adverse events. In response, the Australian government enacted new regulations on October 1, 2024, removing drugs like Ozempic and Mounjaro (GLP-1 RAs) from the pharmacy compounding exemption, effectively making it illegal to compound these specific medications.
The pathway for a drug to be listed on the Pharmaceutical Benefits Scheme (PBS) – Australia’s national pharmaceutical subsidy program – is complex. Pharmaceutical companies must first seek approval to add a specific “indication,” or use, to the drug’s Product Information (PI). Then, they can apply for PBS listing for that indication. The government relies on the advice of the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body, to assess these applications.
The PBAC evaluates the safety, clinical effectiveness, and cost-effectiveness of a medicine, considering alternative treatments. The government is legally obligated to only list a medicine on the PBS if the PBAC recommends it. This process underscores the importance of robust clinical data and rigorous evaluation before a drug becomes widely accessible.
Global Parallels and Ongoing Challenges
Australia’s approach to regulating GLP-1 RA drugs aligns with those of the UK and EU. However, the US operates differently, permitting direct-to-consumer advertising of prescription medications. Both the US Food and Drug Administration (FDA) and the TGA have approved Wegovy for weight loss in addition to type 2 diabetes, and Zepbound and Mounjaro, respectively, for weight loss and obesity.
The FDA has also been grappling with the issue of compounded replicas, with manufacturers taking legal action to prevent their production. In 2023, a Florida judge ruled against Eli Lilly in a case involving compounded versions of its Zepbound drug, though the ruling highlighted the complexities of navigating the Federal Food, Drug and Cosmetic Act. Novo Nordisk has also raised concerns about the quality and purity of compounded semaglutide products, alleging lower concentrations and the presence of impurities.
Affordability and Access Remain Key Concerns
The high cost of these medications remains a significant barrier to access for many. In Australia, Ozempic is available for $31.60 per month with a PBS subsidy, but $134.27 for a private prescription. Mounjaro, currently only available privately, starts at $395 per month, while Wegovy can cost $460 per dose. The Royal Australian College of General Practice (RACGP) notes the disparity, highlighting the financial strain on patients.
Dr. Mark Mellor, a West Australian GP, has advocated for funded access to weight loss treatments, particularly for individuals with a BMI over 40 and associated health impairments. He emphasized that those in lower socioeconomic groups are “disproportionately affected but the least able to afford these treatments.” Wegovy is currently under review by the PBAC, with a decision expected in early November, potentially paving the way for broader subsidies and improved access.
The evolving landscape of semaglutide medications in Australia underscores the delicate balance between addressing public health needs, ensuring patient safety, and navigating the complexities of pharmaceutical regulation and affordability.
